What is Estrella Immunopharma, Inc.'s (ESLA) StockRank?

MoatMap's StockRank for Estrella Immunopharma, Inc. (ESLA) is 3/100, with a Strong Sell signal. This is a composite score combining Quality (16), Value (36), and Momentum (23) factor ranks across MoatMap's 20,000+ stock universe.

Does Estrella Immunopharma, Inc. have an economic moat?

Estrella Immunopharma, Inc. (ESLA) has a Quality factor score of 16/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Estrella Immunopharma, Inc. a buy, hold, or sell?

MoatMap's current signal for Estrella Immunopharma, Inc. (ESLA) is Strong Sell, based on a StockRank of 3/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Estrella Immunopharma, Inc. in?

Estrella Immunopharma, Inc. (ESLA) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

ESLA

STRONG SELLREMOVE

Estrella Immunopharma, Inc. · Healthcare · United States · $62M · Avg Vol: $35K/d

StockRank

P/E (TTM)

—

ROE

—

D/E

—

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Estrella Immunopharma is a micro-cap clinical-stage biotech. It is highly speculative, pre-revenue, and lacks any structural competitive advantages or alignment with our CDMO pricing power theme.

COMPANY DESCRIPTION

Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing T-cell therapies to treat blood cancers and solid tumors. The company's proprietary ARTEMIS platform is designed to target cancer cells while minimizing life-threatening side effects like cytokine release syndrome. This innovative technology positions Estrella as a niche player in the highly competitive oncology immunotherapy market.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	0	0	0	0	—
EPS	-0.05	-0.32	-0.27	-0.35	—
Shares	35M	35M	37M	38M	+9.3%
Debt	6M	15M	180,701	14M	31.5%
Equity	-1M	-12M	4M	-10M	—
Op CF	-1M	-1M	-16M	-2M	—
Inv CF	0	-273,066	5M	—	—
Fin CF	6M	0	13M	2M	—

PRICE (1M)-22.3%

SMA 50SMA 200

$1.01

RSI (14)

37.3

52W High

$3.15

From 52W High

0.3%

SCORE BREAKDOWN

Quality

ROIC (ROA)

-271.5%*1.1

ROE

—N/A

GP/Assets

—N/A

Op. Margin

0.0%40.4

FCF/Assets

-85.6%1.6

Piotroski

—7.2

Int. Cover

—N/A

D/E Ratio

—N/A

Current Ratio

0.24x0.6

Value

P/E (TTM)

—N/A

EV/EBITDA

—N/A

P/FCF

—N/A

P/B

-8.5x97.0

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

32%6.8

RS 6M

-54%20.9

SMA 50/200

0.95x47.1

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

+6%24.7

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$62M

P/E (Forward)

-3.3x

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ESLA are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
ESLA	Estrella Immunopharma, Inc.(you)	$62M	3	STRONG SELL
ATYR	aTyr Pharma, Inc.	$82M	3	STRONG SELL
ANVS	Annovis Bio, Inc.	$81M	1	STRONG SELL
SGMO	Sangamo Therapeutics, Inc.	$87M	3	STRONG SELL
GANX	Gain Therapeutics, Inc.	$86M	3	STRONG SELL
2257.HK	Sirnaomics Ltd.	$82M	7	STRONG SELL
KALA	KALA BIO, Inc.	$104M	2	STRONG SELL
GOSS	Gossamer Bio, Inc.	$79M	9	STRONG SELL
FLNA	Filana Therapeutics, Inc.	$75M	11	STRONG SELL
ANIX	Anixa Biosciences, Inc.	$91M	7	STRONG SELL

Peer medians: ROE -22.6% · P/E 25.3x · Gross margin 44.3%

Estrella Immunopharma, Inc. (ESLA) — Stock Score Summary

Estrella Immunopharma, Inc. (ESLA) has a MoatMap StockRank of 3/100 based on Quality (16/100), Value (36/100), and Momentum (23/100) factor scores. The current signal is STRONG SELL. Estrella Immunopharma is a micro-cap clinical-stage biotech. It is highly speculative, pre-revenue, and lacks any structural competitive advantages or alignment with our CDMO pricing power theme.

Key Financial Metrics

Price	$1.01
Market Cap	$62M
P/E (Forward)	-3.31
Price/Book	-8.55
Gross Margin	0.0%
Operating Margin	0.0%
Free Cash Flow	$-3M

Estrella Immunopharma, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Estrella Immunopharma, Inc.’s (ESLA) StockRank?: MoatMap’s StockRank for Estrella Immunopharma, Inc. (ESLA) is 3/100, with a Strong Sell signal. It is a composite of Quality (16), Value (36), and Momentum (23) factor ranks across MoatMap’s 20,000+ stock universe.
Does Estrella Immunopharma, Inc. have an economic moat?: Estrella Immunopharma, Inc. (ESLA) has a Quality factor score of 16/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Estrella Immunopharma, Inc. a buy, hold, or sell?: MoatMap’s current signal for Estrella Immunopharma, Inc. (ESLA) is Strong Sell, based on a StockRank of 3/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Estrella Immunopharma, Inc. in?: Estrella Immunopharma, Inc. (ESLA) operates in the Healthcare sector, specifically the Biotechnology industry (United States).